Tech Company Financing Transactions

Talaris Therapeutics Funding Round

Surveyor Capital, Viking Global Investors and Aisling Capital participated in a $115 million Series B funding round for Talaris Therapeutics. The funding round was recorded on 10/7/2020.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

201 East Jefferson St. 110B
Louisville, KY 40202
USA

Phone

(502) 569-1059

Website

www.talaristx.com

Email Address

[email protected]

Overview

Talaris is developing a single-dose cell therapy that seeks to free organ transplant recipients of the burdens and toxicities of lifelong immunosuppression, without rejecting their transplanted organ.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Scott Requadt

        

Chief Financial Officer

Gregg Beloff

        

Chief Marketing Officer

Nancy Krieger

        

Chief Scientific Officer

Suzanne Ildstad

        

Vice President

Mary West

        

VP - Finance

Keith McCormick

        

VP - Human Resources

Roderick Purdy

        

VP - Manufacturing

Devin Blass

        

VP - Operations

Suzanne Tollerud

        

VP - Product Management

Eric Gornstein

        

VP - Regulatory Affairs

Andrew Beavis

        

VP - Regulatory Affairs

Sue Graumlich

        

Browse more venture capital transactions:

Prev: 10/7/2020: Federation Bio venture capital transaction
Next: 10/7/2020: Walnut venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary